Ambulatory blood pressure values in the ongoing telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET)

Giuseppe Mancia, Gianfranco Parati, Grzegorz Bilo, Peggy Gao, Robert Fagard, Josep Redon, Istvan Czuriga, Martin Polák, Josè M. Ribeiro, Ramiro Sanchez, Bruno Trimarco, Paolo Verdecchia, Walter Van Mieghem, Koon Teo, Peter Sleight, Salim Yusuf

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

In the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, telmisartan (T; 80 mg daily) and ramipril (R; 10 mg daily) caused similar clinic blood pressure (BP) reductions, with a similar incidence of cardiovascular and renal events. The R+T combination lowered clinic BP somewhat more with no further cardiovascular or renal protection. The aim of this substudy was to see whether these clinic BP changes reflected the changes of 24-hour BP, a BP with a better prognostic value. In 422 patients in whom 24-hour BP monitoring was performed either before or after 6 to 24 months of treatment, demographic and clinical characteristics were similar in the 3 treated groups. Twenty-four-hour systolic BP was similarly reduced by R (-2.0 mm Hg) and T (-2.1 mm Hg), whereas the reduction was more than twice as large in the T+R group (-5.3 mm Hg), which showed a lower on-treatment 24-hour BP also in additional patients (n=408) in whom ambulatory BP was performed only on-treatment. Twenty-four-hour systolic BP was 14 mm Hg lower than clinic systolic BP at baseline, whereas during treatment the 2 values became progressively closer as clinic systolic BP was more tightly controlled and superimposable when clinic systolic BP was

Original languageEnglish
Pages (from-to)1400-1406
Number of pages7
JournalHypertension
Volume60
Issue number6
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Ramipril
Blood Pressure
telmisartan
Kidney

Keywords

  • ambulatory blood pressure
  • angiotensin receptor blockers
  • angiotensin-converting enzyme inhibitors
  • antihypertensive treatment
  • high cardiovascular risk

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Ambulatory blood pressure values in the ongoing telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET). / Mancia, Giuseppe; Parati, Gianfranco; Bilo, Grzegorz; Gao, Peggy; Fagard, Robert; Redon, Josep; Czuriga, Istvan; Polák, Martin; Ribeiro, Josè M.; Sanchez, Ramiro; Trimarco, Bruno; Verdecchia, Paolo; Van Mieghem, Walter; Teo, Koon; Sleight, Peter; Yusuf, Salim.

In: Hypertension, Vol. 60, No. 6, 12.2012, p. 1400-1406.

Research output: Contribution to journalArticle

Mancia, G, Parati, G, Bilo, G, Gao, P, Fagard, R, Redon, J, Czuriga, I, Polák, M, Ribeiro, JM, Sanchez, R, Trimarco, B, Verdecchia, P, Van Mieghem, W, Teo, K, Sleight, P & Yusuf, S 2012, 'Ambulatory blood pressure values in the ongoing telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET)', Hypertension, vol. 60, no. 6, pp. 1400-1406. https://doi.org/10.1161/HYPERTENSIONAHA.112.199562
Mancia, Giuseppe ; Parati, Gianfranco ; Bilo, Grzegorz ; Gao, Peggy ; Fagard, Robert ; Redon, Josep ; Czuriga, Istvan ; Polák, Martin ; Ribeiro, Josè M. ; Sanchez, Ramiro ; Trimarco, Bruno ; Verdecchia, Paolo ; Van Mieghem, Walter ; Teo, Koon ; Sleight, Peter ; Yusuf, Salim. / Ambulatory blood pressure values in the ongoing telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET). In: Hypertension. 2012 ; Vol. 60, No. 6. pp. 1400-1406.
@article{224243d345ec49df9a36b35a14cf6e2b,
title = "Ambulatory blood pressure values in the ongoing telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET)",
abstract = "In the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, telmisartan (T; 80 mg daily) and ramipril (R; 10 mg daily) caused similar clinic blood pressure (BP) reductions, with a similar incidence of cardiovascular and renal events. The R+T combination lowered clinic BP somewhat more with no further cardiovascular or renal protection. The aim of this substudy was to see whether these clinic BP changes reflected the changes of 24-hour BP, a BP with a better prognostic value. In 422 patients in whom 24-hour BP monitoring was performed either before or after 6 to 24 months of treatment, demographic and clinical characteristics were similar in the 3 treated groups. Twenty-four-hour systolic BP was similarly reduced by R (-2.0 mm Hg) and T (-2.1 mm Hg), whereas the reduction was more than twice as large in the T+R group (-5.3 mm Hg), which showed a lower on-treatment 24-hour BP also in additional patients (n=408) in whom ambulatory BP was performed only on-treatment. Twenty-four-hour systolic BP was 14 mm Hg lower than clinic systolic BP at baseline, whereas during treatment the 2 values became progressively closer as clinic systolic BP was more tightly controlled and superimposable when clinic systolic BP was",
keywords = "ambulatory blood pressure, angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, antihypertensive treatment, high cardiovascular risk",
author = "Giuseppe Mancia and Gianfranco Parati and Grzegorz Bilo and Peggy Gao and Robert Fagard and Josep Redon and Istvan Czuriga and Martin Pol{\'a}k and Ribeiro, {Jos{\`e} M.} and Ramiro Sanchez and Bruno Trimarco and Paolo Verdecchia and {Van Mieghem}, Walter and Koon Teo and Peter Sleight and Salim Yusuf",
year = "2012",
month = "12",
doi = "10.1161/HYPERTENSIONAHA.112.199562",
language = "English",
volume = "60",
pages = "1400--1406",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Ambulatory blood pressure values in the ongoing telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET)

AU - Mancia, Giuseppe

AU - Parati, Gianfranco

AU - Bilo, Grzegorz

AU - Gao, Peggy

AU - Fagard, Robert

AU - Redon, Josep

AU - Czuriga, Istvan

AU - Polák, Martin

AU - Ribeiro, Josè M.

AU - Sanchez, Ramiro

AU - Trimarco, Bruno

AU - Verdecchia, Paolo

AU - Van Mieghem, Walter

AU - Teo, Koon

AU - Sleight, Peter

AU - Yusuf, Salim

PY - 2012/12

Y1 - 2012/12

N2 - In the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, telmisartan (T; 80 mg daily) and ramipril (R; 10 mg daily) caused similar clinic blood pressure (BP) reductions, with a similar incidence of cardiovascular and renal events. The R+T combination lowered clinic BP somewhat more with no further cardiovascular or renal protection. The aim of this substudy was to see whether these clinic BP changes reflected the changes of 24-hour BP, a BP with a better prognostic value. In 422 patients in whom 24-hour BP monitoring was performed either before or after 6 to 24 months of treatment, demographic and clinical characteristics were similar in the 3 treated groups. Twenty-four-hour systolic BP was similarly reduced by R (-2.0 mm Hg) and T (-2.1 mm Hg), whereas the reduction was more than twice as large in the T+R group (-5.3 mm Hg), which showed a lower on-treatment 24-hour BP also in additional patients (n=408) in whom ambulatory BP was performed only on-treatment. Twenty-four-hour systolic BP was 14 mm Hg lower than clinic systolic BP at baseline, whereas during treatment the 2 values became progressively closer as clinic systolic BP was more tightly controlled and superimposable when clinic systolic BP was

AB - In the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, telmisartan (T; 80 mg daily) and ramipril (R; 10 mg daily) caused similar clinic blood pressure (BP) reductions, with a similar incidence of cardiovascular and renal events. The R+T combination lowered clinic BP somewhat more with no further cardiovascular or renal protection. The aim of this substudy was to see whether these clinic BP changes reflected the changes of 24-hour BP, a BP with a better prognostic value. In 422 patients in whom 24-hour BP monitoring was performed either before or after 6 to 24 months of treatment, demographic and clinical characteristics were similar in the 3 treated groups. Twenty-four-hour systolic BP was similarly reduced by R (-2.0 mm Hg) and T (-2.1 mm Hg), whereas the reduction was more than twice as large in the T+R group (-5.3 mm Hg), which showed a lower on-treatment 24-hour BP also in additional patients (n=408) in whom ambulatory BP was performed only on-treatment. Twenty-four-hour systolic BP was 14 mm Hg lower than clinic systolic BP at baseline, whereas during treatment the 2 values became progressively closer as clinic systolic BP was more tightly controlled and superimposable when clinic systolic BP was

KW - ambulatory blood pressure

KW - angiotensin receptor blockers

KW - angiotensin-converting enzyme inhibitors

KW - antihypertensive treatment

KW - high cardiovascular risk

UR - http://www.scopus.com/inward/record.url?scp=84870241880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870241880&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.112.199562

DO - 10.1161/HYPERTENSIONAHA.112.199562

M3 - Article

C2 - 23071122

AN - SCOPUS:84870241880

VL - 60

SP - 1400

EP - 1406

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 6

ER -